Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women

Peter L Anderson; Mark A Marzinke; David V Glidden

doi:10.1093/cid/ciad021

Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women

Clin Infect Dis. 2023 May 24;76(10):1850-1853. doi: 10.1093/cid/ciad021.

Authors

Peter L Anderson¹, Mark A Marzinke^{2

3}, David V Glidden⁴

Affiliations

¹ Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
² Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
³ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, USA.

Abstract

Using intraerythrocytic tenofovir-diphosphate data from the emtricitabine/tenofovir disoproxil fumarate arms of HIV Prevention Trials Network (HPTN) 083 (men) and HPTN 084 (women), approximately 99% efficacy was achieved at a lower adherence threshold in HPTN 083 (≥2 doses/week) compared with HPTN 084 (daily), suggesting higher adherence is necessary for women vs men.

Keywords: PrEP; adherence; pharmacology; sex differences; tenofovir.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Anti-HIV Agents* / therapeutic use
Emtricitabine / therapeutic use
Female
HIV
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Male
Medication Adherence
Pre-Exposure Prophylaxis*
Reverse Transcriptase Inhibitors / therapeutic use
Tenofovir / therapeutic use

Substances

Tenofovir
Emtricitabine
Reverse Transcriptase Inhibitors
Anti-HIV Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding